Navigation Links
Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
Date:5/7/2008

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Taisho Pharmaceutical Co., Ltd. initiated a Phase 1 clinical trial of a drug candidate under a GPCR-focused partnership with Arena to develop compounds to treat psychiatric disorders. The drug candidate is a novel oral compound intended for the treatment of a common psychiatric disorder.

"We are very happy to see our long-standing partner, Taisho, effectively continue its efforts under our existing collaboration. We look forward to the Phase 1 results and the continued progress of this program," stated Jack Lief, Arena's President and Chief Executive Officer.

Under an amended agreement with Taisho, which was initially executed in May of 2000 to research a number of different GPCR targets of interest to Taisho, Taisho is responsible for development and commercialization of the drug candidate. Arena is entitled to a low single digit royalty on any product revenues received by Taisho from the sale of the drug candidate. If Taisho out-licenses the drug candidate, Arena is entitled to receive additional payments after Taisho recovers expenses associated with the research and development of the GPCR-focused projects. Arena is not entitled to any further milestone payments under the partnership.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Consolidated Net Profit increased by 43.65 % ... , India Business grew by 20.87% to Rs. 3,971.59 ... Mn Rest of World (ROW) Business grew by 20.67% ... 34.53% to Rs. 977.26 Mn Latin America Business grew ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, today announced ...
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- Delivery of the Report ... placed. Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... in-depth market survey on Global and Chinese Hemodialysis ... information of Hemodialysis Machine including its classification, application ... and China,s top manufacturers of Hemodialysis Machine listing ...
(Date:7/24/2014)... 2014 Cancer patients in the west of ... treatment closer to home when a new radiotherapy center opens ... Systems (NYSE: VAR ) has been selected to ... June for four TrueBeam™ medical linear accelerators. ... efficient radiotherapy and radiosurgery treatments, will replace older treatment machines ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Mass., Dec. 8, 2010 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that although ... of care for first- and second-line treatment of ... replace paclitaxel/carboplatin as the standard second-line treatment for ...
... 8, 2010 Sunridge International (OTC Bulletin Board: ... preparing to start the short term clinical trials needed ... L.L.C., Sunridge,s exclusive distributor for several Middle Eastern countries, ... to attend the start of their clinical trials.  Dr. ...
Cached Medicine Technology:For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients 2For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients 3
(Date:7/24/2014)... PHILADELPHIA For rats bearing human breast tumors, exposure ... to the breast cancer drug tamoxifen, according to data ... the American Association for Cancer Research. The negative effects ... by giving rats a melatonin supplement during the night. ... patients with hormone receptor-positive breast cancer," said Steven M. ...
(Date:7/24/2014)... Denver, CO (PRWEB) July 24, 2014 Ticket ... vs. AS Roma Tickets in Denver at the Sports Authority ... Champions Cup (or World Football Challenge) has brought some of the ... a mini-tournament. With the World Cup still being raved about weeks ... have the chance to see some of the biggest stars in ...
(Date:7/24/2014)... New York (PRWEB) July 24, 2014 ... lawsuits ( http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. ... qualified protective order for plaintiff medical information covered ... Act. According to the July 16th Order, U.S. ... attorneys for Fresenius Medical Care the right ...
(Date:7/24/2014)... (ASAE) announced its 2014 Power of A Award winners, ... Anesthesiologists (ASA). , The ASA Global Humanitarian Outreach ... one of the top honors from ASAE. GHO was ... through education on the global anesthesia crisis and supporting ... was also honored with a Power of A Silver ...
(Date:7/24/2014)... 24, 2014 Pools and beaches are the ... can be dangerous, especially for small children, so Amica ... , According to the Centers for Disease Control and Prevention, ... at risk for water-related injuries and deaths. It’s important to ... water, so Amica is offering the following tips from the ...
Breaking Medicine News(10 mins):Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... Oct. 9 Actor Joe Pantoliano,reveals a personal ... mother,struggled with untreated bipolar disorder, in a guest ... National Alliance on Mental,Illness (NAMI)., Pantoliano,s entry ... a few days before the opening of his ...
... shows , TUESDAY, Oct. 9 (HealthDay News) -- U.S. ... to a treatment for the hereditary, progressive neurological disorder ... molecule called C2-8 appears to reduce HD-related neurological damage ... team from the MassGeneral Institute for Neurological Disorders (MIND), ...
... heart attack risk, study finds , , TUESDAY, Oct. 9 (HealthDay ... who has had a heart attack will have another major ... shown that workplace stress boosts heart woes, but this is ... and other major events, the report,s authors said. , The ...
... Johns Hopkins scientists have developed a potentially novel way ... potent barrages of radiation inside cancer cells, unlike current ... attack from the outside and cause unwanted side effects. ... cells, the new radiation delivery system proved able to ...
... The March of,Dimes congratulates Mario R. Capecchi, Ph.D., ... D.Phil., FRS, former recipients of the,March of Dimes Prize ... Physiology or Medicine. The Nobel Committee announced yesterday ... principles for introducing specific gene,modifications in mice by the ...
... Health plans are expecting premium,rate increases in 2008 ... of 8.2%. This is the fourth consecutive decline in ... survey in September of 2007. The survey,contained 76 responses, ... Separately, the survey notes that the East South Central ...
Cached Medicine News:Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Molecule Promising Against Huntington's Disease 2Health News:Stressful Jobs Hard on the Heart 2Health News:Stressful Jobs Hard on the Heart 3Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Nobel Honors 3 Former March of Dimes Prize Recipients 2
... mini-cells has always distinguished itself by ... tradition continues with the patented XCell ... gel tension wedge in place of ... models makes the XCell SureLock and ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... unit ideal for use in laboratories with low ... set at 12 rpm , Temperature control ... capacity of four 35 x 150mm bottles, eight ... , Consistent, repeatable results achieved with microprocessor ...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Medicine Products: